Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.
企業コードVCYT
会社名Veracyte Inc
上場日Oct 30, 2013
最高経営責任者「CEO」Stapley (Marc A)
従業員数824
証券種類Ordinary Share
決算期末Oct 30
本社所在地6000 Shoreline Court, Suite 300
都市SOUTH SAN FRANCISCO
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号94080
電話番号16502436300
ウェブサイトhttps://www.veracyte.com/
企業コードVCYT
上場日Oct 30, 2013
最高経営責任者「CEO」Stapley (Marc A)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし